Skip to content

Ketone Plasma Kinetics After Oral Intake Of Different MCT

Ketone Plasma Kinetics After Oral Intake Of Different MCT Formulae

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03603782
Enrollment
20
Registered
2018-07-27
Start date
2018-06-04
Completion date
2024-05-31
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This research project is aimed at identifying the MCT formulation matrixes that provide the highest ketoindex values and extended half-life, as well as to provide an initial evaluation of the GI tolerability of the various formula. For comparison, ketones salts and esters (food grade) will be also evaluated.

Detailed description

Monocentric, open, randomized, controlled research project. The global research project will include several testing cycles as described in the figure 1. In each cycle, several research products (up to 4) will be tested on up to 20 participants in a partial or full cross-over design. Once cycle 1 is completed, blood parameters will be analysed and ketoindex will be calculated as area under the curve (AUC) of total ketones (BHB + AcA) over 4h / quantity of ingested MCTs in g. Based on ketoindex and ketones Thalf (T1/2: time to reach half of AUC-infinite of total ketones) values, new products will be developed for cycle 2.

Interventions

DIETARY_SUPPLEMENT2.5% protein

2.5%

DIETARY_SUPPLEMENTprotein 5%

5%

DIETARY_SUPPLEMENTprotein 10%

10%

DIETARY_SUPPLEMENTprotein 15%

15%

DIETARY_SUPPLEMENTA2: Peptamen 1.5 Vanilla without Breakfast

Peptamen withoug breakfast

DIETARY_SUPPLEMENTB2: only breakfast (no product)

only breakfast

DIETARY_SUPPLEMENTC2: 5% protein with breakfast

C2: 5% protein consumed with breakfast

DIETARY_SUPPLEMENTD2: 5% protein 30 min before breakfast

D2: 5% protein consumed 30 min before breakfast

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age: 18-50 years 2. Healthy men and women, based on the medical screening visit and medical history 3. BMI in the normal and overweight range 18.5 ≤ BMI ≤ 27. 4. Able to understand and to sign a written informed consent prior to study entry

Exclusion criteria

1. Any medication possibly impacting the postprandial glucose and insulin response (on anamnesis, to the opinion of the medical expert) 2. Any medication impacting dietary fat absorption and metabolism or impacting postprandial glucose and insulin response, to the opinion of the medical expert 3. Pregnancy (on anamnesis) and/or lactation 4. Known food allergy and food intolerance 5. Individuals undergoing either dietary or exercise mediated weight loss program prescribed by a health care professional 6. Individuals under ketogenic diets, or taking regular ketones products such as MCT, ketone esters or ketone salts (calcium, magnesium, sodium, potassium) 7. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of bier 8. Having given blood within the last month, or willing to make a blood donation until one month following the end of the study 9. Participant having a hierarchical link with the research team members 10. Not expected to follow the protocol. 11. Smokers unable to stop for the day of the visit

Design outcomes

Primary

MeasureTime frameDescription
KetoIndex - plasma concentration4 hoursKetoIndex calculated as area under the plasma concentration versus time curve (AUC) of total ketones (BHB + AcA) over 4 hours after MCT-based products consumption / quantity of ingested MCTs in gram.
total ketones (BHB+ACA) - Half-life time4 hoursHalf-Life time (T ½) calculated as time to reach half of Area under the plasma concentration versus time curve (AUC)-infinite of total ketones (BHB+ACA) after MCT-based products consumption.

Secondary

MeasureTime frameDescription
Ketones blood kinetics - time to maximum concentration4 hoursTime to maximum concentration (Tmax) of total Ketones, BHB, AcA MCT-based products consumption.
Ketones blood kinetics - Half-life time4 hoursHalf-Life time (T ½) measured of total Ketones, BHB, AcA after MCT-based products consumption.
Medium chain fatty acid C8 and C10 - plasma concentration4 hoursMeasure of plasma concentration versus time curve (AUCs) of Medium chain fatty acid C8 and C10 after MCT-based products consumption
Medium chain fatty acid C8 and C10 - concentration4 hoursMaximum plasma Concentration (Cmax) of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption
Medium chain fatty acid C8 and C10 - Time to maximum concentration4 hoursTime to maximum concentration (Tmax) of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption
Medium chain fatty acid C8 and C10 - Half-life time4 hoursHalf-Life time (T ½) measured of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption
Ketones blood kinetic - Plasma concentration4 hours(Total Ketones, BHB, AcA) measured as plasma concentration versus time curve (AUCs) after MCT-based products consumption
Glucose and insulin - peak plasma concentration4 hoursMeasure of maximum plasma concentration (Cmax) of glucose and insuline after MCT-based products consumption
Glucose and insulin - time to maximum concentration4 hoursMeasure of time to maximum concentration (Tmax) of glucose and insuline after MCT-based products consumption
Glucose and insulin- Half-life time4 hoursMeasure of Half-life time (T½) of of glucose and insuline after MCT-based products consumption
Gastro-intestinal tolerability assessment24 hoursGastro-intestinal tolerability assessment with visual analogue scales for each symptom of interest (i.e.) 1) Abdominal discomfort , 2) Decreased appetite, 3) Gastric reflux, 4) Nausea, 5) Diarrhea, 6) Headache). Each scale are from 0 (better outcome) to 100 (worst outcome).
Adverse event incidence24 hoursAdverse events incidence
Glucose and insulin - plasma concentration4 hoursMeasure of plasma concentration versus time curve (AUCs) of glucose and insuline after MCT-based products consumption
Ketones blood kinetics - peak plasma concentration4 hoursPeak Plasma Concentration (Cmax) of total Ketones, BHB, AcA MCT-based products consumption.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026